Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
38.12
+0.52 (1.38%)
At close: Mar 30, 2026, 4:00 PM EDT
38.12
0.00 (0.00%)
After-hours: Mar 30, 2026, 4:10 PM EDT
Corcept Therapeutics Market Cap
Corcept Therapeutics has a market cap or net worth of $4.05 billion as of March 30, 2026. Its market cap has decreased by -29.93% in one year.
Market Cap
4.05B
Enterprise Value
3.51B
1-Year Change
-29.93%
Ranking
Category
Stock Price
$38.12
Market Cap Chart
Since April 14, 2004, Corcept Therapeutics's market cap has increased from $283.00M to $4.05B, an increase of 1,332.85%. That is a compound annual growth rate of 12.89%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 27, 2026 | 4.00B | 9.27% |
| Dec 31, 2025 | 3.66B | -30.67% |
| Dec 31, 2024 | 5.28B | 57.69% |
| Dec 29, 2023 | 3.35B | 53.13% |
| Dec 30, 2022 | 2.19B | -4.35% |
| Dec 31, 2021 | 2.29B | -24.78% |
| Dec 31, 2020 | 3.04B | 119.78% |
| Dec 31, 2019 | 1.38B | -10.36% |
| Dec 31, 2018 | 1.54B | -25.15% |
| Dec 29, 2017 | 2.06B | 155.69% |
| Dec 30, 2016 | 806.10M | 48.81% |
| Dec 31, 2015 | 541.70M | 78.43% |
| Dec 31, 2014 | 303.60M | -5.24% |
| Dec 31, 2013 | 320.40M | 124.53% |
| Dec 31, 2012 | 142.70M | -50.47% |
| Dec 30, 2011 | 288.10M | 3.11% |
| Dec 31, 2010 | 279.40M | 60.85% |
| Dec 31, 2009 | 173.70M | 248.10% |
| Dec 31, 2008 | 49.90M | -59.17% |
| Dec 31, 2007 | 122.20M | 336.43% |
| Dec 29, 2006 | 28.00M | -66.22% |
| Dec 30, 2005 | 82.90M | -41.54% |
| Dec 31, 2004 | 141.80M | -49.89% |
| Apr 14, 2004 | 283.00M | - |
View and export this data all the way back to 2004. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Erasca | 4.65B |
| Amicus Therapeutics | 4.52B |
| CRISPR Therapeutics AG | 4.39B |
| Ligand Pharmaceuticals | 3.90B |
| Centessa Pharmaceuticals | 3.86B |
| Viking Therapeutics | 3.76B |
| Spyre Therapeutics | 3.72B |
| Dianthus Therapeutics | 3.61B |